- South Korea
- /
- Personal Products
- /
- KOSDAQ:A052260
HYUNDAI BIOLANDLtd's (KOSDAQ:052260) Soft Earnings Don't Show The Whole Picture
Soft earnings didn't appear to concern HYUNDAI BIOLAND Co.,Ltd.'s (KOSDAQ:052260) shareholders over the last week. Our analysis suggests that while the profits are soft, the foundations of the business are strong.
The Impact Of Unusual Items On Profit
For anyone who wants to understand HYUNDAI BIOLANDLtd's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit was reduced by ₩2.8b due to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And that's hardly a surprise given these line items are considered unusual. If HYUNDAI BIOLANDLtd doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
Our Take On HYUNDAI BIOLANDLtd's Profit Performance
Unusual items (expenses) detracted from HYUNDAI BIOLANDLtd's earnings over the last year, but we might see an improvement next year. Based on this observation, we consider it likely that HYUNDAI BIOLANDLtd's statutory profit actually understates its earnings potential! Unfortunately, though, its earnings per share actually fell back over the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. For example, we've discovered 2 warning signs that you should run your eye over to get a better picture of HYUNDAI BIOLANDLtd.
This note has only looked at a single factor that sheds light on the nature of HYUNDAI BIOLANDLtd's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
Valuation is complex, but we're here to simplify it.
Discover if HYUNDAI BIOLANDLtd might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSDAQ:A052260
HYUNDAI BIOLANDLtd
Manufactures and sells cosmetic raw materials, health food raw materials, medical devices, and pharmaceutical raw materials worldwide.
Flawless balance sheet and good value.
Market Insights
Community Narratives


Recently Updated Narratives
TAV Havalimanlari Holding will fly high with 25.68% revenue growth

Fiducian: Compliance Clouds or Value Opportunity?

Q3 Outlook modestly optimistic
Popular Narratives

The company that turned a verb into a global necessity and basically runs the modern internet, digital ads, smartphones, maps, and AI.

MicroVision will explode future revenue by 380.37% with a vision towards success
